Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA- conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 10, 2010, Pages 2004-2010

  Virgolini, Irene ^a   Ambrosini, Valentina ^b   Bomanji, Jamshed B ^c   Baum, Richard P ^d   Fanti, Stefano ^b   Gabriel, Michael ^a   Papathanasiou, Nikolaos D ^c   Pepe, Giovanna ^e   Oyen, Wim ^f   De Cristoforo, Clemens ^a   Chiti, Arturo ^e  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d ZENTRALKLINIK BAD BERKA   (Germany)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Indications; Neuroendocrine tumours; Peptides; PET; Procedure guidelines; Tumour Imaging

Indexed keywords

OCTREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; TETRAXETAN; TETRAXETAN GALLIUM 68; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GALLIUM; SINGLE HETEROCYCLIC RINGS;

ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; CHEMISTRY; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; INJECTION; METHODOLOGY; NEOPLASM; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; QUALITY CONTROL; RADIOGRAPHY; SCINTISCANNING; STANDARD;

GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; INJECTIONS; NEOPLASMS; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; QUALITY CONTROL; RESEARCH DESIGN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78649354736     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1512-3     Document Type: Article

References (45)

1. Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42 (7):1134-8.
2. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. (111)In-Pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37 (7):1441-8.
3. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90(2):184-9.
4. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982-93.
5. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389-427.
6. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30 (5):781-93.
7. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S51-61.
8. Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995;25(3):251-61.
9. Briganti V, Sestini R, Orlando C, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3:2385-91.
10. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastro-enteropancreatic tract tumours. Q J Nucl Med 2000;44(1):42-9.
11. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25(10):1396-403.
12. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716-31.
13. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998;25:639-58.
14. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111 pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36:542-49.
15. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancre-atic tumors. J Nucl Med 1997;38(6):853-8.
16. Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1- Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42-8.
17. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617-26.
18. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28(12):1751-7.
19. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30(10):1338-47.
20. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51(5):669-73.
21. Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51(3):353-9.
22. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroen-docrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508-18.
23. Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37(1):46-8.
24. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37 (1):49-57.
25. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 2008;112(11):2447-55.
26. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35(8):1431-8.
27. Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008;62 (10):667-71.
28. Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50 (12):1927-32.
29. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30 (4):281-6.
30. Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 1998;39 (11):1913-7.
31. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuh-macher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningi-omas. J Nucl Med 2005;46(5):763-9.
32. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010;37(1):67-77.
33. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3- octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50 (8):1214-21.
34. Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37 (4):722-7.
35. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3- octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somato-statin receptor positive tumors. Nucl Med Biol 2002;29:147-57.
36. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427-34.
37. EANM Radiopharmacy Committee. Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radio-pharmaceuticals. European Association of Nuclear Medicine; 2007. http://www.eanm.org/scientific-info/ guidelines/gl-radioph-cgrpp.pdf. Accessed 24 June 2010.
38. Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, et al; Radiopharmacy Committee of the EANM. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2010;37:1049-62.
39. Velikyan I, Beyer GJ, Långström B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem 2004;15:554-60.
40. Meyer GJ, Maecke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097-104.
41. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741-8.
42. Di Pierro D, Rizzello A, Cicoria G, Lodi F, Marengo M, Pancaldi D, et al. Radiolabelling, quality control and radiochemical purity assessment of the octreotide analogue 68Ga DOTA NOC. Appl Radiat Isot 2008;66:1091-6.
43. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478-85.
44. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870-5.
45. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72-9.